Targeting the Process of c-MYC Stabilization in Chronic Myelogenous Leukemia
Currently there is no curative therapy for Chronic Myelogenous Leukemia (CML), and patients must remain on the current prescribed treatment, tyrosine kinase inhibitors (TKI), indefinitely. Although many patients can survive in the chronic phase of the disease under TKI treatment, some patients do pr...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en |
| Published: |
Université d'Ottawa / University of Ottawa
2017
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10393/35884 http://dx.doi.org/10.20381/ruor-20167 |